The Challenge and Opportunity of NTRK Inhibitors in Non-Small Cell Lung Cancer

With the development of targeted therapy, non-small cell lung cancer (NSCLC) patients could have more treatment choices if target mutation presents. The neurotrophic tropomyosin receptor kinase (NTRK) has a low prevalence in NSCLC, roughly around 0.5%. FDA had approved two first generation NTRK inhi...

Descripción completa

Detalles Bibliográficos
Autores principales: Qin, Haixia, Patel, Manish R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8954929/
https://www.ncbi.nlm.nih.gov/pubmed/35328336
http://dx.doi.org/10.3390/ijms23062916
_version_ 1784676214241230848
author Qin, Haixia
Patel, Manish R.
author_facet Qin, Haixia
Patel, Manish R.
author_sort Qin, Haixia
collection PubMed
description With the development of targeted therapy, non-small cell lung cancer (NSCLC) patients could have more treatment choices if target mutation presents. The neurotrophic tropomyosin receptor kinase (NTRK) has a low prevalence in NSCLC, roughly around 0.5%. FDA had approved two first generation NTRK inhibitors, larotrectinib and entrectinib. Both medications have excellent CNS penetration. This manuscript will review available data on targeting NTRK fusions in NSCLC and mechanisms of drug resistance.
format Online
Article
Text
id pubmed-8954929
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-89549292022-03-26 The Challenge and Opportunity of NTRK Inhibitors in Non-Small Cell Lung Cancer Qin, Haixia Patel, Manish R. Int J Mol Sci Review With the development of targeted therapy, non-small cell lung cancer (NSCLC) patients could have more treatment choices if target mutation presents. The neurotrophic tropomyosin receptor kinase (NTRK) has a low prevalence in NSCLC, roughly around 0.5%. FDA had approved two first generation NTRK inhibitors, larotrectinib and entrectinib. Both medications have excellent CNS penetration. This manuscript will review available data on targeting NTRK fusions in NSCLC and mechanisms of drug resistance. MDPI 2022-03-08 /pmc/articles/PMC8954929/ /pubmed/35328336 http://dx.doi.org/10.3390/ijms23062916 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Qin, Haixia
Patel, Manish R.
The Challenge and Opportunity of NTRK Inhibitors in Non-Small Cell Lung Cancer
title The Challenge and Opportunity of NTRK Inhibitors in Non-Small Cell Lung Cancer
title_full The Challenge and Opportunity of NTRK Inhibitors in Non-Small Cell Lung Cancer
title_fullStr The Challenge and Opportunity of NTRK Inhibitors in Non-Small Cell Lung Cancer
title_full_unstemmed The Challenge and Opportunity of NTRK Inhibitors in Non-Small Cell Lung Cancer
title_short The Challenge and Opportunity of NTRK Inhibitors in Non-Small Cell Lung Cancer
title_sort challenge and opportunity of ntrk inhibitors in non-small cell lung cancer
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8954929/
https://www.ncbi.nlm.nih.gov/pubmed/35328336
http://dx.doi.org/10.3390/ijms23062916
work_keys_str_mv AT qinhaixia thechallengeandopportunityofntrkinhibitorsinnonsmallcelllungcancer
AT patelmanishr thechallengeandopportunityofntrkinhibitorsinnonsmallcelllungcancer
AT qinhaixia challengeandopportunityofntrkinhibitorsinnonsmallcelllungcancer
AT patelmanishr challengeandopportunityofntrkinhibitorsinnonsmallcelllungcancer

Ejemplares similares